International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency

被引:162
作者
Lichtman, Stuart M.
Wildiers, Hans
Launay-Vacher, Vincent
Steer, Christopher
Chatelut, Etienne
Aapro, Matti [1 ]
机构
[1] Doyen IMO Clin Genolier, CH-1272 Genolier, Switzerland
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[3] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[4] Hop La Pitie Salpetriere, Paris, France
[5] Univ Toulouse 3, F-31062 Toulouse, France
[6] Inst Claudius Regaud, Toulouse, France
关键词
clinical practice recommendations; elderly; cancer; renal insufficiency; creatinine clearance; serum creatinine; dosing adjustments;
D O I
10.1016/j.ejca.2006.11.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A SIOG taskforce was formed to discuss best clinical practice for elderly cancer patients with renal insufficiency This manuscript outlines recommended dosing adjustments for cancer drugs in this population according to renal function. Dosing adjustments have been made for drugs in current use which have recommendations in renal insufficiency and the elderly, focusing on drugs which are renally eliminated or are known to be nephrotoxic. Recommendations are based on pharmacokinetic and/or pharmacodynamic data where available. The taskforce recommend that before initiating therapy, some form of geriatric assessment should be conducted that includes evaluation of comorbidities and polypharmacy, hydration status and renal function (using available formulae). Within each drug class, it is sensible to use agents which are less likely to be influenced by renal clearance. Pharmacokinetic and pharmacodynamic data of anticancer agents in the elderly are needed in order to maximise efficacy whilst avoiding unacceptable toxicity. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:14 / 34
页数:21
相关论文
共 266 条
  • [1] AAPRO M, IN PRESS ANN ONCOL
  • [2] AAPRO M, 2005, SIOG NEWSLETTER, V1
  • [3] Gemcitabine - a safety review
    Aapro, MS
    Martin, C
    Hatty, S
    [J]. ANTI-CANCER DRUGS, 1998, 9 (03) : 191 - 201
  • [4] Ibandronate: New options in the treatment of osteoporosis
    Adami, S
    Viapiana, O
    [J]. DRUGS OF TODAY, 2003, 39 (11) : 877 - 886
  • [5] Adkins JC, 1997, DRUGS, V53, P1005
  • [6] ALBERTS DS, 1985, INVEST NEW DRUG, V3, P101
  • [7] ALBERTS DS, 1978, AM ASS CANC RES, V19, P77
  • [8] ALLEN LM, 1975, CLIN PHARMACOL THER, V17, P492
  • [9] Anastasia P J, 2001, Clin J Oncol Nurs, V5, P9
  • [10] Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: a position statement
    Anavekar, N
    Bais, R
    Carney, S
    Eris, J
    Gallagher, M
    Johnson, D
    Jones, G
    Sikaris, K
    Lonergan, M
    Ludlow, M
    Mackie, J
    Mathew, T
    May, S
    McBride, G
    Meerkin, M
    Peake, M
    Power, D
    Snelling, P
    Voss, D
    Walker, R
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2005, 183 (03) : 138 - +